Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma

Acta Oncologica

Volumn 46, Issue 2, 2007, Pages 230-233

  Lind, Pehr A ^a,b   Naucler, Gisela ^a   Holm, Agneta ^a   Gubanski, Michael ^a,b   Svensson, Christer ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETAMETHASONE; BILIRUBIN; DOXORUBICIN; ONDANSETRON;

ADVANCED CANCER; AGED; ANTIEMETIC ACTIVITY; ARTICLE; ASCITES; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER REGISTRY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; HAND FOOT SYNDROME; HEART DISEASE; HISTOLOGY; HUMAN; LEUKOPENIA; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; LIVER METASTASIS; LIVER TUMOR; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIODIAGNOSIS; SYSTEMIC THERAPY; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; POLYETHYLENE GLYCOLS; SURVIVAL; TREATMENT OUTCOME;

EID: 33847029662     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600693473     Document Type: Article

References (17)

1. Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991;36:962-72.
2. Bartlett DL, Carr BI, Marsh JW. Cancer of the Liver. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 986-1008.
3. Ihde DC, Kane RC, Cohen MH, McIntire KR, Minna JD. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 1977;61:1385-7.
4. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
5. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987;7:660-4.
6. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346-53.
7. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
8. Mann H, Whitney D. On a test whether one or two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60.
9. Jonckheere AR. A distribution-free k-sample test against ordered alternatives. Biometrika 1954;41:133-45.
10. Siegel S, Castellan Jr N. Nonparametric statistics, 2nd ed. New York: McGraw-Hill; 1988.
11. Halm U, Etzrodt G, Schiefke I, Schmidt F, Witzigmann H, Mossner J, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000;11:113-4.
12. Valle JW, Dangoor A, Beech J, Sherlock DJ, Lee SM, Scarffe JH, et al. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): Results of a phase II study. Br J Cancer 2005;92:628-30.
13. Thomas MB, Zhu AX. Hepatocellular carcinoma: The need for progress. J Clin Oncol 2005;23:2892-9.
14. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005;23:8093-108.
15. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-63.
16. Schwartz J, Schwartz M, Lehrer D, Coll M, Kinkhabwala M, Sung M, et al. Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastasis and without invasion of the portal vein. J Clin Oncol 2005;23:338a. Abstract 4122.
17. Rizell M, Cahlin C, Friman S, Hafstrom L, Lonn L, Olausson M, et al. Impressive regression of primary liver cancer after treatment with sirolimus. Acta Oncol 2005;44:496.